Andreas U. Gasser
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Andreas U. Gasser has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Christine Stephanie Zuern
Division of Cardiology, Department of Medicine (P.B.M., S.A., S.O., F.M., C.S.Z., M.K.), University Hospital Basel, Switzerland
2 shared publications Alain M. Bernheim
Department of Cardiology, Triemli Hospital Zurich, Zurich, Switzerland
1 shared publication- Alain M. Bernheim
Department of Cardiology, Stadtspital Zürich , Birmensdorferstrasse 497, 8063 Zürich
1 shared publication - Andreas Müller
Department of Cardiology Triemli Hospital Zurich Zurich Switzerland
1 shared publication Andreas S. Müller
Department of Cardiology, Triemli Hospital Zurich, Zurich, Switzerland
1 shared publicationChristian Sticherling
Department of Cardiology, University Hospital Basel, Basel, Switzerland
1 shared publication
Latest Publications
- Open Access
- 20 March 2026
- Published by Elsevier in Heart Rhythm O2
- Vol. 7 (6) , 1095-1104
Discrimination of atrial fibrillation burden using cardiac magnetic resonance imaging
- 20 March 2026
- Published by Elsevier in Heart Rhythm O2
- Vol. 7 (6) , 1095-1104
Open AccessDiscrimination of atrial fibrillation burden using cardiac magnetic resonance imaging
- Open Access
- 28 October 2025
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 27 (11)
Adverse outcomes in patients with atrial fibrillation and a pacemaker: a cohort study
Aims: Patients with atrial fibrillation (AF) are at a high risk of adverse cardiovascular outcomes. Little is known about the specific population of AF patients with implanted pacemaker (PM) and their prognosis. Therefore, we aimed to compare the risks of adverse outcomes in AF patients with and without PM. Methods and results: Data from two Swiss prospective, multicentre cohort studies (Swiss-AF, Beat-AF) (n = 3675) with yearly follow-ups (FUs) up to 8 years were analysed. The first main outcome was major adverse cardiovascular events (MACE), a composite of stroke or transient ischaemic attack, myocardial infarction, cardiovascular death, and systemic embolism. The second main outcome was hospitalization for heart failure (HF). Secondary outcomes were the individual components of MACE. We performed time-updated Cox regression analyses to investigate the association of PM and outcomes. Median age was 71.4 years, 28.8% female, 445 (12.1%) patients had a PM at baseline, and 238 additional patients (7.4%, 1.05%/year) received a PM over a median FU of 7 years. Patients with a PM had higher incidence rates for MACE and HF (5.97 and 5.08 per 100 patient-years, respectively), compared to patients without a PM (3.37 and 2.61 per 100 patient-years, respectively). After multivariable adjustment, we found no independent association of PM and MACE (aHR [95% CI] 1.12 [0.95–1.33; P = 0.183]) or HF (aHR [95% CI] 1.14 [0.94–1.37; P = 0.180]). We found consistent results for the individual components of MACE. Conclusion: Patients with AF and a PM experienced an increased rate of adverse cardiovascular outcomes. However, the PM itself was not independently associated with these outcomes.
- 28 October 2025
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 27 (11)
Open AccessAdverse outcomes in patients with atrial fibrillation and a pacemaker: a cohort study
Aims: Patients with atrial fibrillation (AF) are at a high risk of adverse cardiovascular outcomes. Little is known about the specific population of AF patients with implanted pacemaker (PM) and their prognosis. Therefore, we aimed to compare the risks of adverse outcomes in AF patients with and without PM. Methods and results: Data from two Swiss prospective, multicentre cohort studies (Swiss-AF, Beat-AF) (n = 3675) with yearly follow-ups (FUs) up to 8 years were analysed. The first main outcome was major adverse cardiovascular events (MACE), a composite of stroke or transient ischaemic attack, myocardial infarction, cardiovascular death, and systemic embolism. The second main outcome was hospitalization for heart failure (HF). Secondary outcomes were the individual components of MACE. We performed time-updated Cox regression analyses to investigate the association of PM and outcomes. Median age was 71.4 years, 28.8% female, 445 (12.1%) patients had a PM at baseline, and 238 additional patients (7.4%, 1.05%/year) received a PM over a median FU of 7 years. Patients with a PM had higher incidence rates for MACE and HF (5.97 and 5.08 per 100 patient-years, respectively), compared to patients without a PM (3.37 and 2.61 per 100 patient-years, respectively). After multivariable adjustment, we found no independent association of PM and MACE (aHR [95% CI] 1.12 [0.95–1.33; P = 0.183]) or HF (aHR [95% CI] 1.14 [0.94–1.37; P = 0.180]). We found consistent results for the individual components of MACE. Conclusion: Patients with AF and a PM experienced an increased rate of adverse cardiovascular outcomes. However, the PM itself was not independently associated with these outcomes.